[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-360861-105":59,"doc-detail-360861-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","naa50-mediated-slu7-stabilization-promotes-cisplatin-resistance-in-bladder-cancer-via-regulating-map3k3-mrna-nuclear-export-and-p38-mapk-activation","NAA50-mediated SLU7 stabilization promotes cisplatin resistance in bladder cancer via regulating MAP3K3 mRNA nuclear export and p38 MAPK activation","","Cisplatin-based chemotherapy is the first-line treatment for muscle-invasive bladder cancer, yet chemoresistance limits clinical effectiveness. RNA-binding proteins are increasingly linked to post-transcriptional mechanisms driving resistance, but the role of the splicing factor SLU7 in bladder cancer remains unclear. In cisplatin-treated cohorts, SLU7 correlates with poor outcomes. SLU7 knockdown suppresses MAP3K3, inhibits p38 MAPK signaling, and restores cisplatin sensitivity. Mechanistically, NAA50 acetylates and stabilizes SLU7, enabling MAP3K3 mRNA nuclear export to activate p38 signaling.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/naa50-mediated-slu7-stabilization-promotes-cisplatin-resistance-in-bladder-cancer-via-regulating-map3k3-mrna-nuclear-export-and-p38-mapk-activation/360861/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/naa50-mediated-slu7-stabilization-promotes-cisplatin-resistance-in-bladder-cancer-via-regulating-map3k3-mrna-nuclear-export-and-p38-mapk-activation/360861.png","ImageObject",300,407,{"name":92,"@type":93},"Well Done","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is cisplatin resistance a major barrier in muscle-invasive bladder cancer?","Question",{"text":112,"@type":113},"Cisplatin-based chemotherapy is first-line, but resistance develops in a substantial fraction of patients, causing treatment failure, progression, and poor survival.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was SLU7 linked to cisplatin resistance in bladder cancer?",{"text":117,"@type":113},"SLU7 expression was analyzed in two independent cisplatin-treated cohorts, where higher SLU7 independently predicted worse survival outcomes. Functional assays using cisplatin-resistant cell lines showed that SLU7 knockdown suppresses MAP3K3 and inhibits p38 MAPK activation, restoring cisplatin sensitivity.",{"name":119,"@type":110,"acceptedAnswer":120},"What molecular axis is proposed to drive resistance and how does it work?",{"text":121,"@type":113},"The study identifies an NAA50–SLU7–MAP3K3–p38 MAPK regulatory axis. NAA50 catalyzes N-terminal acetylation that stabilizes SLU7, enabling direct binding to MAP3K3 mRNA and promoting its nuclear export to activate p38 signaling; inhibiting NAA50 with Naa50-IN-1 reverses resistance in vitro and in vivo.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},360861,1790211597,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},5909892210082,"https://ap-avatar.wpscdn.com/avatar/56001069da27c9f41e8?x-image-process=image/resize,m_fixed,w_180,h_180&k=1789614185077863061","Cellular Oncology (2026) 49:94  \n[https://doi.org/10.1007/s13402-026-01219-0](https://doi.org/10.1007/s13402-026-01219-0)  \nRESEARCH  \nNAA50-mediated SLU7 stabilization promotes cisplatin resistance in bladder cancer via regulating MAP3K3 mRNA nuclear export and p38 MAPK activation  \nBenlin Wang1 · Xianchong Zheng2,3 · Qingsheng Hua1 · Feng Zou1 · Tao Huang1 · Jiawei Chen1  \nReceived: 22 January 2026 / Accepted: 3 May 2026 © The Author(s) 2026  \nAbstract  \nBackground Cisplatin-based chemotherapy is first-line for muscle-invasive bladder cancer (BLCA), but chemoresistance remains the primary barrier to clinical efficacy. RNA-binding proteins (RBPs) orchestrate post-transcriptional gene regulation and are increasingly implicated in cancer chemoresistance; however, the role and regulatory mechanism of the splicing factor RBP SLU7 in BLCA cisplatin resistance remain completely unknown.  \nMethods We analyzed SLU7 expression and clinical prognosis in two independent cisplatin-treated BLCA cohorts (GSE87304, GSE169455) . Cisplatin-resistant BLCA cell lines (T24-CIS, UMUC3-CIS) were established for functional assays (CCK-8, qRT-PCR, western blotting). Molecular interactions were validated by RIP-qPCR, immunofluorescence(IF), RNA-FISH, nucleocytoplasmic fractionation, co-immunoprecipitation (co-IP), and mass spectrometry (MS) . In vivo therapeutic efficacy was assessed in BLCA xenograft models.  \nResults SLU7 was significantly upregulated in cisplatin-resistant BLCA cells, and high SLU7 expression independently predicted poor cancer-specific survival (CSS) and recurrence-free survival (RFS) in cisplatin-treated patients. SLU7 knockdown suppressed MAP3K3 expression, inhibited p38 MAPK pathway, and restored cisplatin sensitivity. Mechanistically, SLU7 directly bound MAP3K3 mRNA and promoted its nuclear export—a non-canonical function independent of its canonical splicing activity. MS and Co-IP identified NAA50 as the upstream regulator that catalyzes N-terminal acetylation of SLU7 to prevent its ubiquitin-proteasomal degradation, thereby sustaining SLU7 stability. Pharmacological inhibition of NAA50 with Naa50-IN-1 destabilized SLU7, blocked the MAP3K3-p38 axis, and reversed cisplatin resistance in vitro and in vivo. Conclusions We uncover a novel NAA50–SLU7–MAP3K3-p38 MAPK regulatory axis that drives cisplatin resistance in BLCA. NAA50-mediated N-terminal acetylation stabilizes SLU7, which in turn facilitates MAP3K3 mRNA nuclear export to activate p38 MAPK signaling. Targeting NAA50 represents a promising therapeutic strategy to overcome cisplatin resistance in BLCA, and SLU7 serves as a predictive biomarker for cisplatin response.  \nKeywords BLCA · Cisplatin resistance · SLU7 · MAP3K3 · NAA50  \nBenlin Wang and Xianchong Zheng contributed equally to this work.  \n􀀍 Xianchong Zheng [zhengxc@sysucc.org.cn](zhengxc@sysucc.org.cn)  \n􀀍 Tao Huang [sddlhuangtao@163.com](sddlhuangtao@163.com)  \n􀀍 Jiawei Chen [miwaicjw@163.com](miwaicjw@163.com)  \n1 Department of Urology, The Eighth Affiliated Hospital, Southern Medical University (The First People’s Hospital of Shunde, Foshan), Foshan, China  \n2 State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou 510060, China  \n3 Department of Urology, Sun Yat-Sen University Cancer Center, Guangzhou 510060, China  \n1 Introduction  \nBladder cancer (BLCA) is one of the most prevalent urological malignancies worldwide. Muscle-invasive bladder cancer (MIBC) accounts for over 70% of BLCA-related mortality due to its high invasiveness, frequent recurrence, and distant metastasis [1, 2] . Cisplatin-based chemotherapy, as the cornerstone of neoadjuvant, adjuvant, and palliative treatment for MIBC, has significantly improved clinical outcomes over the past decades [3] . However, the acquisition ofcisplatin resistance—either de novo or acquired during treatment—occurs in over 40% of patients, leading to treatment failur","cbCaik8HssXBCWnH","https://ap.wps.com/l/cbCaik8HssXBCWnH","pdf",2986245,17,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# Introduction","[{\"question\":\"Why is cisplatin resistance a major barrier in muscle-invasive bladder cancer?\",\"answer\":\"Cisplatin-based chemotherapy is first-line, but resistance develops in a substantial fraction of patients, causing treatment failure, progression, and poor survival.\"},{\"question\":\"How was SLU7 linked to cisplatin resistance in bladder cancer?\",\"answer\":\"SLU7 expression was analyzed in two independent cisplatin-treated cohorts, where higher SLU7 independently predicted worse survival outcomes. Functional assays using cisplatin-resistant cell lines showed that SLU7 knockdown suppresses MAP3K3 and inhibits p38 MAPK activation, restoring cisplatin sensitivity.\"},{\"question\":\"What molecular axis is proposed to drive resistance and how does it work?\",\"answer\":\"The study identifies an NAA50–SLU7–MAP3K3–p38 MAPK regulatory axis. NAA50 catalyzes N-terminal acetylation that stabilizes SLU7, enabling direct binding to MAP3K3 mRNA and promoting its nuclear export to activate p38 signaling; inhibiting NAA50 with Naa50-IN-1 reverses resistance in vitro and in vivo.\"}]","NAA50-mediated SLU7 stabilization promotes cisplatin resistance in bladder cancer via regulating MAP3K3 mRNA nuclear export and p38 MAPK activation | PDF",1790141848,43,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f9578c31d9e7466150783baf4291aafa.webp",983,1305,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d664e039c43ff9329c2836c25eb1402b.webp",982,1304,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b90da2d329a794c1d46bb74bac8220dc.webp",981,1303,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5a0e95fea2a3952db2afe23b121efccf.webp",980,1301]